Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Period

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,142 result(s) found for: Period. Displaying page 3 of 708.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-005299-36 Sponsor Protocol Number: EXEVIR0101 Start Date*: 2021-04-21
    Sponsor Name:ExeVir Bio BV
    Full Title: A 2-part Clinical Study Including a First-in-Human, Open-label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double-blind, Placebo-controlled Part (Phase 2) to Evaluate the Effica...
    Medical condition: Subjects hospitalised for COVID 19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000580-78 Sponsor Protocol Number: EMPAtia Start Date*: 2022-02-02
    Sponsor Name:The Children’s Memorial Health Institute
    Full Title: "The assessment of effectiveness and safeness of utilizing empagliflozin in the treatment of neutropenia of patients suffering from glycogenolysis type Ib"
    Medical condition: neutropenia and / or abnormal neutrophil function in glycogenosis I b
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015768-33 Sponsor Protocol Number: EMR700773-003/BMN162-503 Start Date*: 2011-01-04
    Sponsor Name:BioMarin International Ltd.
    Full Title: A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patient...
    Medical condition: Phenylketonuria
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10034873 Phenylketonuria (PKU) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) DE (Completed) AT (Completed) CZ (Completed) PT (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000347-28 Sponsor Protocol Number: KF10004/10 Start Date*: 2012-09-03
    Sponsor Name:Grünenthal GmbH
    Full Title: Efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain
    Medical condition: moderate to severe localized chronic post-operative neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) ES (Completed) IT (Completed) DK (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006082-32 Sponsor Protocol Number: 2293/2007 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Female steroid hormones and protection from cardiovascular risk: staminal endothelial progenitor cells and menopause.
    Medical condition: Postmenopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051775 Postmenopause LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003701-25 Sponsor Protocol Number: 7035-CL-0014 Start Date*: 2013-12-09
    Sponsor Name:Tacurion Pharma Inc
    Full Title: A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio ...
    Medical condition: Nocturia associated with nocturnal polyuria
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064016 Nocturnal polyuria LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000451-14 Sponsor Protocol Number: 112896 Start Date*: 2017-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, single group, multi-centric, post marketing surveillance (PMS) to monitor the reactogenicity and safety of oral live attenuated human rotavirus (HRV) vaccine, Rotarix when administered acc...
    Medical condition: Healthy volunteers (Active immunisation of infants from the age of 6 weeks for prevention of gastroenteritis due to rotavirus infection).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001546-28 Sponsor Protocol Number: 111664 Start Date*: 2015-06-11
    Sponsor Name:Smithkline Beecham Pvt Limited
    Full Title: Open, multi-centric, post-marketing surveillance (PMS) to evaluate the reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccin...
    Medical condition: Rotavirus Gastroenteritis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004070-42 Sponsor Protocol Number: A4250PBCpruritus Start Date*: 2014-12-09
    Sponsor Name:Sahlgrenska Academy
    Full Title: An Exploratory, Phase IIa Cross-Over Study to Demonstrate the Efficacy and Safety of A4250 in Patients with Primary Biliary Cirrhosis and Cholestatic Pruritus
    Medical condition: Primary biliary cirrhosis complicated by cholestatic pruritus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002125-30 Sponsor Protocol Number: AELIX-003 Start Date*: 2019-05-09
    Sponsor Name:AELIX Therapeutics
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection
    Medical condition: Human immunodeficiency virus type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: View results
    EudraCT Number: 2021-006811-27 Sponsor Protocol Number: 21I-Pxp10 Start Date*: 2022-06-27
    Sponsor Name:IBSA INSTITUT BIOCHIMIQUE SA
    Full Title: A multicentre, prospective, open-label clinical trial with a piroxicam 14 mg medicated plaster in the treatment of painful osteoarthritic first metatarsophalangeal joint (hallux rigidus)
    Medical condition: Painful osteoarthritic first metatarsophalangeal joint (hallux rigidus)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10019092 Hallux rigidus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002756-27 Sponsor Protocol Number: N01349 Start Date*: Information not available in EudraCT
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A multicenter, open-label, single-arm study to evaluate the pharmacokinetics, efficacy, and safety of brivaracetam in neonates with repeated electroencephalographic seizures
    Medical condition: Electroencephalographic neonatal seizures
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Prematurely Ended) CZ (Completed) HU (Completed) NL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000838-34 Sponsor Protocol Number: NOE-TCS-201 Start Date*: 2023-04-04
    Sponsor Name:Noema Pharma AG
    Full Title: A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Doubleblind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of ...
    Medical condition: Tuberous Sclerosis Complex
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10080584 Tuberous sclerosis complex PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005896-12 Sponsor Protocol Number: CBYL719F12401 Start Date*: 2021-10-20
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (E...
    Medical condition: PIK3CA-related overgrowth spectrum (PROS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10081236 PIK3CA related overgrowth spectrum PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004685-32 Sponsor Protocol Number: P02978 Start Date*: 2005-08-22
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transf...
    Medical condition: Platelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GR (Completed) AT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003966-29 Sponsor Protocol Number: BCX7353-302 Start Date*: Information not available in EudraCT
    Sponsor Name:BioCryst Pharmaceuticals Inc.
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in...
    Medical condition: Hereditary angioedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) IE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) DK (Completed) HU (Completed) CZ (Completed) AT (Completed) NL (Ongoing) BE (Completed) ES (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-001193-25 Sponsor Protocol Number: D9830C00003 Start Date*: 2006-09-21
    Sponsor Name:AstraZeneca AB
    Full Title: A 4 week randomised, double blind, placebo controlled, parallel group, phase II, PoP study to assess the efficacy and safety of AZD1981 in adult patients with asthma.
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001812-65 Sponsor Protocol Number: CVAL489K2301 Start Date*: 2006-08-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney D...
    Medical condition: Chronic kidney disease is characterized by a progressive decline of glomerular filtration rate (GFR), which occurs irrespectively of the cause of the renal damage once a critical nephron mass has b...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002481-40 Sponsor Protocol Number: TAK-935-3002 Start Date*: 2021-07-22
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subj...
    Medical condition: Lennox-Gastaut Syndrome (LGS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA IT (Completed) FR (Completed) ES (Completed) LV (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001153-10 Sponsor Protocol Number: X4P-001-103 Start Date*: 2020-02-05
    Sponsor Name:X4 Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
    Medical condition: WHIM Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010512 Congenital immunodeficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) ES (Ongoing) PL (Completed) AT (Completed) DE (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 00:16:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA